Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Amyotrophic Lateral Sclerosis

    Current Location

    Search
    Amyotrophic Lateral Sclerosis
    Show Map
    Map View
    Your Location

    Popular Searches

    By Condition

    Depression Clinical Trials

    Anxiety Clinical Trials

    Schizophrenia Clinical Trials

    ADHD Clinical Trials

    Bipolar Disorder Clinical Trials

    Multiple Sclerosis Clinical Trials

    Autism Clinical Trials

    Treatment Resistant Depression Clinical Trials

    Borderline Personality Disorder Clinical Trials

    Social Anxiety Disorder Clinical Trials

    Parkinson's Disease Clinical Trials

    Alzheimer's Disease Clinical Trials

    By Location

    Clinical Trials in California

    Clinical Trials in Florida

    Clinical Trials in Texas

    Clinical Trials in New York

    Clinical Trials in Ohio

    Clinical Trials in Illinois

    Clinical Trials in Pennsylvania

    Clinical Trials in Michigan

    Clinical Trials in North Carolina

    Clinical Trials in Massachusetts

    Clinical Trials in Missouri

    Clinical Trials in Minnesota

    Other People Viewed

    By Subject

    27 Multiple Sclerosis Trials near Richmond, VA

    69 Multiple Sclerosis Trials near San Diego, CA

    53 Multiple Sclerosis Trials near New York, NY

    Top Multiple Sclerosis Clinical Trials

    Top Primary Progressive Multiple Sclerosis Clinical Trials

    26 Multiple Sclerosis Trials near Dallas, TX

    16 Multiple Sclerosis Trials near Knoxville, TN

    58 Clinical Trials near Minnesota

    Top Gallbladder Clinical Trials

    Top Ependymoma Clinical Trials

    Top Lipedema Clinical Trials

    Top Sle Clinical Trials

    By Trial

    Antisense Oligonucleotide Therapy for ALS

    Usnoflast for ALS

    ALN-SOD for ALS

    RE104 for Adjustment Disorder

    CNS10-NPC-GDNF for ALS

    PTC857 for ALS

    TurbAlign for Sinus Surgery

    Task Practice Interventions for Executive Function

    Internal Fixation vs Nonoperative Care for Pelvic Fractures

    Lateral Soft Tissue Release for Bunions

    L-Serine Safety for ALS

    Olaparib + Radium-223 for Prostate Cancer

    Related Searches

    Top Alzheimers-disease Clinical Trials near Lancaster, CA

    Pioglitazone for Fatigue in Breast Cancer

    TMS for Nicotine Addiction

    NC410 + FOLFIRINOX + Nivolumab for Pancreatic Cancer

    Nutrition Coaching for Pancreatic Cancer

    Pembrolizumab + Chemoradiotherapy for Bladder Cancer

    IV vs Oral Iron Therapy for Anemia in Pregnancy

    ADEL-Y01 for Alzheimer's Disease

    Avapritinib + Decitabine for Systemic Mastocytosis

    Exercise Training for PTSD

    Autologous Blood Membrane Technique for Gum Recession

    Mirdametinib + BGB-3245 for Advanced Cancer

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      65 Amyotrophic Lateral Sclerosis Trials Near You

      Power is an online platform that helps thousands of Amyotrophic Lateral Sclerosis patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      ION363 for ALS

      Columbus, Ohio
      This trial is testing a new drug called ION363 to help people with a specific genetic form of ALS (FUS-ALS). The study will see if the drug can help these patients live longer and maintain their abilities better. Participants will receive the drug for a period of time, then all will get the drug for an extended duration.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:10 - 65

      Key Eligibility Criteria

      Disqualifiers:Ventilation, HIV, Hepatitis, Others
      Must Be Taking:Edaravone, Riluzole, Relyvrio, Others

      89 Participants Needed

      Multiple Treatments for ALS

      Columbus, Ohio
      The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Unstable Medical Condition, Cancer, Others
      Must Be Taking:Riluzole, Edaravone

      1500 Participants Needed

      AMX0035 for ALS

      Columbus, Ohio
      The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Tracheostomy, Renal Insufficiency, Heart Failure, Others
      Must Be Taking:Riluzole, Edaravone

      664 Participants Needed

      Ranolazine for ALS

      Columbus, Ohio
      The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Heart Disease, Liver Disease, Others
      Must Not Be Taking:Ranolazine, QT Prolonging Drugs

      72 Participants Needed

      RE104 for Adjustment Disorder

      Columbus, Ohio
      The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Schizophrenia, Psychotic, Others
      Must Be Taking:Antidepressants

      100 Participants Needed

      VHB937 for ALS

      Columbus, Ohio
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset). The study comprises a core double-blind (DB) 40-week treatment period followed by an open label extension (OLE).

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Cardiac Conditions, Liver Disease, Psychiatric Disease, Cancer, Others
      Must Not Be Taking:Prohibited Medications

      251 Participants Needed

      Latozinemab Continuation for Neurodegenerative Disease

      Cincinnati, Ohio
      Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Heart Disease, Liver Disease, Kidney Disease, Others
      Must Be Taking:Latozinemab

      35 Participants Needed

      Medical Cannabis for Chronic Pain

      Sandusky, Ohio
      This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
      Stay on current meds
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:7+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Suicidality, Psychosis, Others

      200000 Participants Needed

      Masitinib for ALS

      Lexington, Kentucky
      This trial tests if a new medication taken with riluzole can help ALS patients by reducing inflammation and protecting nerve cells. ALS patients are targeted because current treatments are not very effective.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Dementia, Uncontrolled Diseases, FVC < 60%, Others
      Must Be Taking:Riluzole

      495 Participants Needed

      Rho Kinase Inhibitor for ALS

      Lexington, Kentucky
      This trial is testing a new drug called WP-0512 to see if it can help people with ALS. It targets patients who have had ALS symptoms for a few years and meet specific health criteria. The drug aims to slow down the progression of ALS symptoms.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Neuromuscular Diseases, Ventilation, Others
      Must Be Taking:Riluzole, Edaravone, Phenylbutyrate, TUDCA

      40 Participants Needed

      MN-166 for ALS

      Pittsburgh, Pennsylvania
      A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Hepatic Insufficiency, Psychiatric Disorder, Dementia, Others
      Must Not Be Taking:High-dose Vitamin B12

      234 Participants Needed

      PTC857 for ALS

      Detroit, Michigan
      This trial is testing a new drug called PTC857 to see if it can help people with ALS. Participants will either receive PTC857 or a non-active substance. If they complete the initial treatment, they can continue taking PTC857 for an extended period to further assess its effects.

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      307 Participants Needed

      Implantable Brain-Computer Interface for Paralysis

      Pittsburgh, Pennsylvania
      The Synchron motor neuroprosthesis (MNP) is intended to be used in subjects with severe motor impairment, unresponsive to medical or rehabilitative therapy and a persistent functioning motor cortex. The purpose of this research is to evaluate safety and feasibility. The MNP is a type of implantable brain computer interface which bypasses dysfunctional motor neurons. The device is designed to restore the transmission of neural signal from the cerebral cortex utilized for neuromuscular control of digital devices, resulting in a successful execution of non-mechanical digital commands.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:21 - 75

      Key Eligibility Criteria

      Disqualifiers:Immunosuppression, Anesthesia Unsuitability, Allergies, Others

      6 Participants Needed

      Usnoflast for ALS

      Pittsburgh, Pennsylvania
      Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Unstable Psychiatric Disease, Dementia, Substance Abuse, Others
      Must Not Be Taking:Steroids, Colchicine, Anti-IL-1

      240 Participants Needed

      XT-150 for ALS

      Detroit, Michigan
      This is a Phase 1, open-label, multi-center safety study of XT-150 in adult participants with Amyotrophic Lateral Sclerosis (ALS). Participants providing informed consent and meeting all study eligibility criteria will be enrolled in the study and will receive a single injection of XT-150 at the Baseline visit. Follow-up visits will occur over 180 days (6 months) after the injection. 8 participants (4 participants per dose level) will be enrolled sequentially in up to 2 ascending, single dose cohorts: Cohort 1: 1.5 mg XT-150 Cohort 2: 4.5 mg XT-150
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Cardiac Conditions, COPD, Cancer, Others
      Must Not Be Taking:Tofersen, Investigational Drugs

      8 Participants Needed

      ALN-SOD for ALS

      London, Ontario
      This study is researching an experimental drug called ALN-SOD (called "study drug"). This study is focused on people with amyotrophic lateral sclerosis (ALS) caused by a change in a gene called the superoxide dismutase-1 (SOD1) gene. This type of ALS is known as "SOD1-ALS". This is the first time that ALN-SOD will be given to people. The aim of the study is to see how safe and tolerable the study drug is. The study is looking at several other research questions, including: * The effect the study drug has on specific biomarkers, which are substances in the blood or in the fluid that surrounds the brain and spinal cord, known as cerebrospinal fluid (CSF) * How much study drug is in the blood and in the CSF, at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) * What effects the study drug has on ALS symptoms

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Dementia, Uncontrolled Psychiatric Disease, Others
      Must Not Be Taking:Tofersen

      42 Participants Needed

      AMX0114 for ALS

      London, Ontario
      This study is a placebo-controlled Phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide (ASO) AMX0114 in adult participants with amyotrophic lateral sclerosis (ALS).

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Tracheostomy, Liver Dysfunction, Others
      Must Be Taking:Riluzole, Edaravone

      48 Participants Needed

      LY4256984 for ALS

      London
      The purpose of this study is to evaluate how well LY4256984 is tolerated and what side effects may occur in participants with sporadic amyotrophic lateral sclerosis (ALS). The study drug will be administered intrathecally (IT) into the spine. Blood tests will be performed to check how much LY4256984 gets into the bloodstream and how long it takes the body to eliminate it.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular, Renal, Hepatic, Neurological, Others

      32 Participants Needed

      MSC-NTF (NurOwn) for ALS

      Chicago, Illinois
      The goal of this two-part clinical trial is: 1\) to evaluate the safety and efficacy of Debamestrocel - MSC-NTF (NurOwn) compared to placebo in participants with early symptomatic ALS and moderate disease presentation in ALS; followed by 2) further evaluation by providing NurOwn to all participants in an open label extension period. Researchers will compare NurOwn to a placebo (a look-alike substance that contains no drug) to evaluate the efficacy of NurOwn compared to placebo in the treatment of participants with ALS. Participants will: Receive NurOwn or a placebo every 8 weeks for 24 weeks. After that, every participant will receive NurOwn every 8 weeks for an additional 24 weeks. They will visit the clinic approximately every 8 weeks for checkups and tests.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Prior Stem Cell Therapy, Cancer, Other Motor Neuron Diseases, Others

      200 Participants Needed

      Gene Therapy for ALS

      Chicago, Illinois
      This is the study of AMT-162 in Participants with SOD1-ALS and is designed to evaluate the safety, tolerability, and exploratory efficacy of intrathecally administered gene therapy AMT-162. AMT-162-001 is a Phase 1/2, multi-center, single ascending dose study.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:C9orf72 Expansion, SOD1 Variants, Others
      Must Not Be Taking:SOD1 Suppression, AAV Gene Therapy

      20 Participants Needed

      Why Other Patients Applied

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78
      Match to a Amyotrophic Lateral Sclerosis Trial

      Dazucorilant for ALS

      Hamilton, Ontario
      This trial is testing a new medication called dazucorilant to see if it can help people with ALS. ALS is a serious disease with few treatment options, so new treatments are needed. The medication might work by slowing down the disease or making symptoms less severe.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Non-ALS Neurologic Disorder, HIV, Others
      Must Not Be Taking:Glucocorticoids

      249 Participants Needed

      Speech Perception for ALS

      University Park, Pennsylvania
      In this study, we will evaluate how solo, naive listeners perceive the speech of people with amyotrophic lateral sclerosis (ALS) and age-matched speakers produced across interactive and non-interactive contexts with an unfamiliar, naive interlocutor.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Speech, Language, Neurological Disorders, Others

      1300 Participants Needed

      Communication Strategies for ALS

      University Park, Pennsylvania
      The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and age-matched speakers. The question is, What are the effects of communicative interaction on verbal communication in people with ALS? Participants will read words and sentences while they are in a solo setting and interactive setting.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Stroke, Cognitive Impairment, Others

      300 Participants Needed

      Tofersen for ALS

      Chicago, Illinois
      This trial is testing a medication called tofersen in adults who have a genetic mutation that can lead to ALS, a serious nerve disease. These individuals show early signs of nerve damage. Tofersen works by lowering harmful proteins in the body to protect nerves and potentially delay or prevent the disease.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B, Hepatitis C, Others
      Must Not Be Taking:Riluzole, Edaravone, Ursodoxicoltaurine, Others

      158 Participants Needed

      Digoxin for ALS

      Chicago, Illinois
      This clinical trial is being conducted to learn about safety and tolerability of digoxin in ALS individuals. Additionally, this trial aims to better understand if digoxin has an effect on slowing neurodegeneration in ALS.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Unstable Medical Condition, Cancer, Transplant, Cardiac Disorders, Others
      Must Not Be Taking:Amiodarone, Quinidine

      40 Participants Needed

      Communicative Interaction for ALS

      University Park, Pennsylvania
      The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and their caregivers. The question is, What are the effects of communicative interaction on verbal communication in people with ALS when they interact with their caregivers and does this change over time? Participants will read words and sentences while they are interacting with their caregivers.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Stroke, Cognitive Impairment, Others

      152 Participants Needed

      tDCS for Slowing ALS Progression

      Chicago, Illinois
      This trial is testing a new treatment that uses electrical signals sent to the brain, monitored by doctors remotely. It aims to help people with ALS keep their muscles working better for longer. The goal is to see if this method can slow down the loss of motor function in ALS patients.

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      100 Participants Needed

      AP-101 for ALS

      Toronto, Ontario
      This trial is testing a new treatment called AP-101 to see if it is safe and well-tolerated. It focuses on people with familial and sporadic ALS, a condition that affects nerve cells and muscle control. Researchers want to understand how AP-101 moves through the body and its effects on ALS symptoms.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Cognitive Impairment, Severe Cardiovascular, Others
      Must Be Taking:Riluzole, Edaravone

      63 Participants Needed

      Intravenous Immunoglobulin for ALS

      Toronto, Ontario
      The goal of this study is to evaluate the safety and feasibility of IVIg administration in conjunction with primary motor cortex BBB opening using the Next Generation Dome Helmet (NGDH) FUS in adult participants with ALS.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Cardiac Disease, Hypertension, Bleeding Disorders, Depression, Auto-immune Conditions, Others
      Must Not Be Taking:Aspirin, Anticoagulants, Avastin, Others

      6 Participants Needed

      QRL-201 for ALS

      Toronto, Ontario
      This trial tests the safety and tolerability of QRL-201, a new drug, in people with ALS. The drug is given directly into the spinal fluid to better reach the nervous system.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:SOD1/FUS Gene Variants, Other Studies, Stem Cell/gene Therapy, Neurological Disorders, Others

      64 Participants Needed

      123

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Amyotrophic Lateral Sclerosis clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Amyotrophic Lateral Sclerosis clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Amyotrophic Lateral Sclerosis trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Amyotrophic Lateral Sclerosis is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Amyotrophic Lateral Sclerosis medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Amyotrophic Lateral Sclerosis clinical trials?

      Most recently, we added Speech Perception for ALS, Acamprosate for ALS and Cromolyn Sodium for ALS to the Power online platform.

      Are there any promising cures for ALS?

      There is still no one-shot “cure” for ALS, but several newer drugs—riluzole, edaravone, AMX0035, and the gene-specific therapy tofersen—can modestly slow the disease, and dozens of gene, antisense, immune-modulating and stem-cell treatments are now in late-stage clinical trials. Specialists therefore view ALS care as a rapidly evolving field: staying connected to an ALS center, asking about genetic testing, and monitoring clinical-trial options offer the best chance to benefit from these emerging therapies while comprehensive supportive care maximizes quality of life today.

      What is the longest lifespan after ALS diagnosis?

      Most people with ALS live 2–5 years, but about 5–10 % are alive at 10 years and fewer than 1 % reach 20 years—usually those who are younger, have a slow limb-onset form, and/or use long-term ventilatory support. The longest well-documented survivor was physicist Stephen Hawking, who lived roughly 55 years after symptom onset, showing that while such extreme longevity is possible, it is an extraordinary outlier rather than the norm.

      Can you still get hard with ALS?

      ALS usually doesn’t damage the automatic nerves that create an erection, so many men can still “get hard.” If weakness, fatigue, mood issues or medicines make erections unreliable, standard treatments like Viagra-type pills, vacuum pumps, position changes or counselling often help—so bring any problems up with your neurologist or a urologist early.

      What are the 7 stages of ALS?

      Doctors don’t follow one standard “7-stage” chart for ALS; most use the King’s system (one body region affected → two → three → need for a feeding tube → need for breathing support → death) or the Milano-Torino (MiToS) system, which grades loss of independence in 1, 2, 3, or 4 key functions before death. The public 7-step list you may see online (symptom onset, diagnosis, independent phase, assisted independence, moderate loss, advanced loss, end-of-life) is simply a lay summary of these milestones. Ask your neurologist which staging scale they use so you can match care plans, equipment, and treatments to your current stage.

      What is the best hospital for ALS?

      There isn’t one universally “best” hospital for ALS; the goal is to be seen at an ALS Association-Certified Treatment Center of Excellence or similar multidisciplinary clinic, where neurologists, respiratory, rehab, nutrition and social-work specialists collaborate—an approach shown to prolong survival. Use the ALS Association (als.org/clinics) or MDA clinic finder to locate the nearest accredited program, then weigh travel distance, insurance coverage and access to clinical trials; highly regarded examples include Mass General’s Healey Center (MA), Johns Hopkins (MD), Mayo Clinic (MN/FL), Northwestern’s Les Turner Center (IL), Cedars-Sinai and UCSF (CA).

      What is the new name for ALS?

      There is no officially adopted “new” name—amyotrophic lateral sclerosis (ALS) is still the formal medical term used in disease classifications worldwide. People may hear it called “motor neurone/neuron disease (MND)” in the UK and other countries or “Lou Gehrig’s disease” in North America, but these are regional synonyms rather than a recent name change.

      Who is doing research on ALS?

      ALS research is a worldwide team effort: leading university clinics (e.g., Johns Hopkins, Mass General/Harvard, Mayo Clinic, University of Sheffield), large research networks such as NEALS, Project MinE, Answer ALS and Target ALS, government funders (NIH, CDC, European JPND), patient-driven nonprofits (ALS Association, ALS TDI) and biotech/pharma companies like Biogen, Amylyx and BrainStorm all run studies. To see exactly who is doing what and how to join in, visit the NEALS Trial Finder or ClinicalTrials.gov, or enroll in the CDC National ALS Registry, which sends research invitations to registered patients.

      Does walking help with ALS?

      Gentle, short-distance walking can help people with ALS keep their joints moving, maintain endurance, and feel better emotionally, but it will not stop the disease itself. The key is to walk at a pace that does not leave you wiped out after 30 minutes, use braces or a helper to prevent falls, and adjust or switch to seated or pool exercises as weakness advances under the guidance of your neurologist or physical therapist.

      Can you recover from amyotrophic lateral sclerosis?

      Today there is no way to “recover” from ALS because once the motor nerves die they cannot be rebuilt; the goal of treatment is to slow the disease and manage symptoms. Medicines such as riluzole, edaravone, the new combination pill AMX0035, and the gene-targeted drug tofersen (for certain inherited cases) plus coordinated breathing, nutrition and physical therapy can extend survival and preserve independence for months to years, while dozens of clinical trials continue to search for a true cure.

      Does IVIg help ALS?

      Current research shows that IVIg does not meaningfully slow down or improve ALS; at best, a few small studies saw short-lived effects that disappeared within weeks and could not be reproduced. Because of this, expert guidelines advise against using IVIg for ALS outside of clinical trials—discuss other FDA-approved options (riluzole, edaravone) and participation in research studies with your neurologist instead.